SCHEMBL2686355

SCHEMBL2686355

COc1cccc(NC(=O)C(N)c2ccc(C(=O)Nc3nn(-c4ccccc4)cc3N)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.54
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
NLRP3 Q96P20 1/20 0.48
TRPV1 Q8NER1 1/20 0.48
TP53 P04637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ADORA3 P0DMS8 4/20 0.45
TSHR P16473 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KCNK9 Q9NPC2 2/20 0.44
KCNK3 O14649 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.43
EGFR P00533 1/20 0.42
FGFR1 P11362 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686893 0.85 HDAC1 (0.54) HDAC1RAB9ANPC1TP53ALDH1A1
SCHEMBL2685935 0.80 HDAC1 (0.55) HDAC1RAB9ANPC1TP53ALDH1A1
SCHEMBL1754072 0.79 HDAC1 (0.60) HDAC1RAB9ATP53ADORA3KDM4E
SCHEMBL2684960 0.79 TSHR (0.40) HDAC1ADORA3TSHRKDM4EMAPT
SCHEMBL2685998 0.78 RAB9A (0.45) HDAC1RAB9ANPC1TP53PKM
SCHEMBL13950308 0.78 HDAC1 (0.47) HDAC1RAB9ATP53KMT2ASMN1; SMN2
SCHEMBL1689347 0.78 HDAC1 (0.55) HDAC1RAB9ATP53ADORA3KDM4E
SCHEMBL8231601 0.77 HDAC1 (0.49) HDAC1RAB9ANPC1NLRP3TRPV1
SCHEMBL2686090 0.77 NPC1 (0.49) RAB9ANPC1TP53ALDH1A1PKM
SCHEMBL14312744 0.76 HDAC1 (0.55) HDAC1RAB9ATP53ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991226-B1 INHIBITORS OF HISTONE DEACETYLASE MERCK SHARP & DOHME (US) 2013-03-20 EP claimed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US claimed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US claimed
EP-1991226-A2 INHIBITORS OF HISTONE DEACETYLASE Merck & Co., Inc. (US) 2008-11-19 EP claimed
WO-2007100657-A2 INHIBITORS OF HISTONE DEACETYLASE MERCK & CO., INC. (US) 2007-09-07 WO claimed
EP-1991226-B1 INHIBITORS OF HISTONE DEACETYLASE MERCK SHARP & DOHME (US) 2013-03-20 EP disclosed
EP-1991226-B1 INHIBITORS OF HISTONE DEACETYLASE MERCK SHARP & DOHME (US) 2013-03-20 EP disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069250-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC6 HDAC1 1/4885RAB9A 4368/4885NPC1 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.